[en] Introduction: Tobacco is a worldwide relevance problem. According to the WHO (World Health Organization) tobacco causes the death of more than 8 million people a year. In addition, it has negative effects on both smokers and people who inhale tobacco smoke. Children are also affected by this second-hand smoke, which can cause serious damage, including death. To prevent tobacco from being the cause of disease and death, new drugs, varenicline and bupropion, have been made available to the population to improve the efficacy of the therapies known so far for smoking cessation. Objective: The objective of our study is to identify the real efficacy of varenicline and bupropion for smoking cessation. Methodology: To answer the study question and the stated objectives, a systematic review was carried out. A search for clinical trials was conducted in Pubmed, Scopus and Cochrane. The search strategy was limited to studies in the last 11 years in english or spanish. Results: Both vareniclina and bupropion are more effective than any tobacco cessation therapy used so far. Varenicline (OR 2,15-4,7) has greater efficacy than bupropion (OR 0,86-2,84), especially in the long term, but some authors argue that this efficacy is not clinically significant. The combination of both therapies (OR 1,09-3,71) improves the effectiveness of their use as monotherapy without increasing adverse events. Also is important to mention the association between determined genes like CYP2B6 and its variant rs8109525 and the efficacy of the treatment. Conclusions: There is an increase in efficacy with the use of these drugs either as monotherapy or combining both drugs. Furthermore, in the treatment with varenicline and bupropion their haven´t been identified serious adverse events. Research must continue in this area to find new ways to improve the effectiveness of these treatments.

[gl] Introdución: O tabaco é un problema de relevancia mundial. Segundo a OMS o tabaco causa a morte de mais de 8 millóns de persoas ao ano. Ademais ten efectos negativos tanto en fumadores como nas persoas que inhalan o fume do tabaco. Os nenos tamén vense afectados por este fume alleo, podendo provocarlles graves danos incluso a morte. Para evitar que o tabaco siga sendo o causante de enfermidades e mortes púxose a disposición da poboación novidosos fármacos, vareniclina e bupropión, que melloran a eficacia das terapias coñecidas ata a fecha para a deshabituación tabáquica. Obxectivo: O obxectivo do noso estudo é identificar a eficacia real da vareniclina e o bupropión para a deshabituación tabáquica. Metodoloxía: Para responder á pregunta de investigación e ós obxectivos plantexados, levouse a cabo una revisión sistemática. Realizouse una procura de ensaios clínicos en Pubmed, Scopus e Cochrane. A estratexia de búsqueda realizouse sobre estudos nos últimos 11 anos en inglés e español. Resultados: Tanto a vareniclina como o bupropión teñen una eficacia maior que calquera terapia para a deshabituación tabáquica utilizada ata a fecha. A vareniclina (OR 2,15-4,7) ten una eficacia maior que o bupropión (OR 0,86-2.84) sobre todo a longo prazo, pero algúns autores indican que esta eficacia non é clinicamente significativa. A combinación de ambas terapias (OR 1,09-3,71) mellora a eficacia do seu uso como monoterapia sen aumentar as reacción adversas. Ademais, é importante destacar a asociación entre variantes en determinados xenes como o CYP2B6 e a sua variante rs8109525 e a eficacia do tratamento. Conclusións: Existe un aumento da eficacia coa utilización destes fármacos xa sexa en monoterapia ou combinación de ambos fármacos. Ademais, no tratamento con vareniclina ou bupropión non se identificaron reaccións adversas graves. Debese continuar coa investigación nesta área para encontrar novas formas de mellorar a eficacia destes tratamentos.